We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

LISBON, Jan 31 (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than ...

Com tudo isso, será que o Velho Continente está preparado para Donald Trump ou foi pego cochilando na direção (de novo)? Uma tonelada de cocaína, três brasileiros inocentes e a busca por um ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

O economista Álvaro Almeida é o novo director executivo do Serviço Nacional de Saúde (SNS), anunciou o Governo esta terça-feira. Álvaro Santos de Almeida substitui António Gandra d ...

Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...

O novo diretor executivo do SNS tem um doutoramento em Economia pela London School of Economics and Science e é professor associado na Faculdade de Economia da Universidade do Porto. Nas autárquicas ...

Luxury fashion house LVMH has reclaimed its title as Europe’s most valuable company from Novo Nordisk, as early signs of a luxury comeback coincided with fresh struggles for the Danish Ozempic ...

Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...